Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. - Wikidata - wikimedia - TriplyDB

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

http://www.wikidata.org/entity/Q33408279

about

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.Trial Watch: Lenalidomide-based immunochemotherapy.

P2860

Q33429608-6E44E28F-3D82-4B69-A5E0-696F990A9FA2 Q36270115-61A54F3B-E527-429E-98F6-D4583D8F31D2 Q38646057-52ECEF1F-D04B-453F-B29E-EDF214670D33 Q38813996-E8C3544B-38E2-4628-A412-129EAD3F2D93 Q40796265-A3670040-B8E2-4DD8-A359-71900FB8AF0B Q41619260-AFCA4B2F-6784-40D0-B626-0DB9C01F66E6 Q42737828-CBFC545D-D276-488B-89A9-66F6ED16EC3E

P2860

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

http://www.wikidata.org/entity/Q33408279

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I clinical trial of lena ...... patients with advanced cancer.

@ast

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

type

label

Phase I clinical trial of lena ...... patients with advanced cancer.

@ast

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

prefLabel

Phase I clinical trial of lena ...... patients with advanced cancer.

@ast

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

P1433

Q33408279-BEF521F4-E19F-4C9C-AA43-8FEAA111AC00

P1476

Q33408279-801DF7CC-8408-4755-A722-1B82E4FBF460

P2093

Q33408279-5683FECA-08DD-4637-823B-70B9AABF18D2

Q33408279-7A1BA3F2-21E4-467D-975B-45476E9C2E70

Q33408279-80D30256-A4D3-4730-8C64-7F2FAFB46909

Q33408279-84C64F1A-D4B5-4680-A457-57A3010C56CB

Q33408279-A14FC0EC-7F4E-4A28-B4B0-1B42C329C24A

Q33408279-ACA198E8-6A90-4207-A2C3-9ABCC7BAD07C

Q33408279-E879D349-1393-4613-B7B2-513360CFA6DF

P2860

Q33408279-0F914786-3204-46C1-81AF-095C3128C187

Q33408279-28CABE49-98B1-403E-A66F-8E7D64DE65C7

Q33408279-35591A64-5A39-46CE-AA76-382B2A3E468E

Q33408279-3F4E627B-C270-4094-832B-164E2111B2B8

Q33408279-4A2D0DC8-3EDB-4E53-892C-7B7A06CADFC2

Q33408279-74FF7EA7-5B64-4407-B3E3-217BC159CEB5

Q33408279-7698AF04-E737-451C-939F-DBA312DCEDE0

Q33408279-AD45DB85-73C3-490E-9529-E75DF6D9DD08

Q33408279-B6790FA9-DAC5-44C5-B369-49CAF243589A

Q33408279-BDC95D07-76FB-4EA1-8CB3-B6CB36B0B727

P2888

Q33408279-48826886-F764-4E62-870D-3A1DE464E5CB

P304

Q33408279-0DBB2051-137F-4730-AAD5-339F69E156E2

P31

Q33408279-E0B64E66-AD5D-4F4A-BC1D-C3F2BCD66A7C

P356

Q33408279-BBA8C02F-72CE-4CA4-8A23-E653EEA395AC

P433

Q33408279-DAC6F1C0-3B40-46E1-8F10-F30BAC519688

P478

Q33408279-79E39A37-D75D-47D7-84FA-E7F49A57C40B

P50

Q33408279-78DC8C80-069F-4BB3-B49B-23FE43A82D84

Q33408279-8FFB05AB-E3B4-4A27-AB5C-EA7E001F74C1

Q33408279-9392A13D-7017-4975-AB74-C776F12EEAB3

Q33408279-969D4687-856E-405B-8E3E-49CAF6D83A9A

Q33408279-CD7A3FC8-3EC4-4C10-BCBC-C88157CD6A57

Q33408279-E66432F6-99D0-4B4F-A1B1-757EC9425916

Q33408279-EB9F80A5-652B-4EFC-BD70-1EF655AD9578

P577

Q33408279-C6799FBF-6973-4F60-BDC1-A5B277622E40

P6179

Q33408279-96EB6FE2-3503-4F5C-8245-D4B870D5BF4E

P698

Q33408279-03362FFB-BA60-4D3E-9F88-7BD99A6F023D

P921

Q33408279-E2ED1DAB-E9BA-4044-8787-70FDA76738FB

P932

Q33408279-5244D2CA-C029-4DAE-B5DC-51BF6A70971C

P356

S10637-013-9966-3

P1433

Investigational New Drugs

P1476

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

P2093

Agop Y Bedikian

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald Falchook

http://www.w3.org/2001/XMLSchema#string

Jennifer Wheler

http://www.w3.org/2001/XMLSchema#string

Merrill Kies

http://www.w3.org/2001/XMLSchema#string

Robert A Wolff

http://www.w3.org/2001/XMLSchema#string

Shell Laday

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Lenalidomide therapy for metastatic renal cell carcinoma.

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

P2888

s10637-013-9966-3

P304

279-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-013-9966-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Prasanth Ganesan

Razelle Kurzrock

Apostolia Maria Tsimberidou

Sarina Piha-Paul

P577

2013-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001726300

http://www.w3.org/2001/XMLSchema#string

P698

23756764

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

5730367

http://www.w3.org/2001/XMLSchema#string